Medical management of Cushing’s disease: what is the future?

gan Fleseriu, Maria, Petersenn, Stephan
Cyhoeddwyd 2012

New avenues in the medical treatment of Cushing’s disease: corticotroph tumor targeted therapy

gan Fleseriu, Maria, Petersenn, Stephan
Cyhoeddwyd 2013

Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study

gan Petersenn, Stephan, Houchard, Aude, Sert, Caroline, Caron, Philippe J.
Cyhoeddwyd yn Pituitary (2019)

Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas

gan Biller, Beverly MK, Colao, Annamaria, Petersenn, Stephan, Bonert, Vivien S, Boscaro, Marco
Cyhoeddwyd 2010

Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study

gan Caron, Philippe J., Bevan, John S., Petersenn, Stephan, Houchard, Aude, Sert, Caroline, Webb, Susan M.
Cyhoeddwyd yn Pituitary (2015)

Use of Oral Concomitant Medications in Patients With Acromegaly

gan Petersenn, Stephan, Houchard, Aude, Schneider, Maria del Pilar, Ribeiro-Oliveira, Antonio, Neggers, Sebastian Jcmm
Cyhoeddwyd yn J Endocr Soc (2021)

The Rational Use of Pituitary Stimulation Tests

gan Petersenn, Stephan, Quabbe, Hans-Jürgen, Schöfl, Christof, Stalla, Günter K, von Werder, Klaus, Buchfelder, Michael
Cyhoeddwyd 2010

Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial

gan Caron, Philippe J., Bevan, John S., Petersenn, Stephan, Flanagan, Daniel, Tabarin, Antoine, Prévost, Gaëtan, Maisonobe, Pascal, Clermont, Antoine
Cyhoeddwyd 2014

Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT® validation study

gan Giustina, Andrea, Bronstein, Marcello D., Chanson, Philippe, Petersenn, Stephan, Casanueva, Felipe F., Sert, Caroline, Houchard, Aude, Melmed, Shlomo
Cyhoeddwyd yn Pituitary (2019)

Pituitary Disease in Pregnancy: Special Aspects of Diagnosis and Treatment?

gan Petersenn, Stephan, Christ-Crain, Mirjam, Droste, Michael, Finke, Reinhard, Flitsch, Jörg, Kreitschmann-Andermahr, Ilonka, Luger, Anton, Schopohl, Jochen, Stalla, Günter
Cyhoeddwyd yn Geburtshilfe Frauenheilkd (2019)

Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing’s disease: 12-month, Phase III pasireotide study

gan Findling, James W., Fleseriu, Maria, Newell-Price, John, Petersenn, Stephan, Pivonello, Rosario, Kandra, Albert, Pedroncelli, Alberto M., Biller, Beverly M. K.
Cyhoeddwyd yn Endocrine (2016)

Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria

gan Rinke, Anja, Maintz, Christoph, Müller, Lothar, Weber, Matthias M., Lahner, Harald, Pavel, Marianne, Saeger, Wolfgang, Houchard, Aude, Ungewiss, Hanna, Petersenn, Stephan
Cyhoeddwyd yn Exp Clin Endocrinol Diabetes (2021)

High variability in baseline urinary free cortisol values in patients with Cushing’s disease

gan Petersenn, S, Newell-Price, J, Findling, J W, Gu, F, Maldonado, M, Sen, K, Salgado, L R, Colao, A, Biller, B M K
Cyhoeddwyd yn Clin Endocrinol (Oxf) (2014)

Long-term treatment of Cushing’s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial

gan Petersenn, S., Salgado, L. R., Schopohl, J., Portocarrero-Ortiz, L., Arnaldi, G., Lacroix, A., Scaroni, C., Ravichandran, S., Kandra, A., Biller, B. M. K.
Cyhoeddwyd yn Endocrine (2017)

Ectopic Cushing' syndrome caused by a neuroendocrine carcinoma of the mesentery

gan Petersenn Stephan, Buchfelder Michael, Moche Michael, Tannapfel Andrea, Kluge Regine, Witzigmann Helmut, Lincke Thomas, Fasshauer Mathias, Kratzsch Juergen, Paschke Ralf, Koch Christian A
Cyhoeddwyd 2006-04-01

Ectopic Cushing' syndrome caused by a neuroendocrine carcinoma of the mesentery

gan Fasshauer, Mathias, Lincke, Thomas, Witzigmann, Helmut, Kluge, Regine, Tannapfel, Andrea, Moche, Michael, Buchfelder, Michael, Petersenn, Stephan, Kratzsch, Juergen, Paschke, Ralf, Koch, Christian A
Cyhoeddwyd 2006

A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with...

gan Mercado, Moises, Borges, Fatima, Bouterfa, Hakim, Chang, Tien-Chun, Chervin, Alberto, Farrall, Andrew J, Patocs, Attila, Petersenn, Stephan, Podoba, Jan, Safari, Mitra, Wardlaw, Joanna
Cyhoeddwyd 2007

SAGIT(®): clinician-reported outcome instrument for managing acromegaly in clinical practice—development and results from a pilot study

gan Giustina, Andrea, Bevan, John S., Bronstein, Marcello D., Casanueva, Felipe F., Chanson, Philippe, Petersenn, Stephan, Thanh, Xuan-Mai Truong, Sert, Caroline, Houchard, Aude, Guillemin, Isabelle, Melmed, Shlomo
Cyhoeddwyd yn Pituitary (2015)

Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study

gan Boscaro, M., Bertherat, J., Findling, J., Fleseriu, M., Atkinson, A. B., Petersenn, S., Schopohl, J., Snyder, P., Hughes, G., Trovato, A., Hu, K., Maldonado, M., Biller, B. M. K.
Cyhoeddwyd 2013

Histological criteria for atypical pituitary adenomas – data from the German pituitary adenoma registry suggests modifications

gan Miermeister, Christian P., Petersenn, Stephan, Buchfelder, Michael, Fahlbusch, Rudolf, Lüdecke, Dieter K., Hölsken, Annett, Bergmann, Markus, Knappe, Hans Ulrich, Hans, Volkmar H., Flitsch, Jörg, Saeger, Wolfgang, Buslei, Rolf
Cyhoeddwyd yn Acta Neuropathol Commun (2015)